1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch
Book a demo
-
  1. My Preqin
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch
  1. My Preqin
Book a demo

Anji Pharmaceuticals Inc.

Have updates for this profile?  Please contribute data

About Key Contacts
= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2018

Location

Shanghai China

Primary Industry

Pharmaceuticals

About

Based in Shanghai, China, and established in 2018, Anji Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the R&D of innovative drugs for metabolic diseases. The company's CEO, Ph.D. Brian Hubbard, has over 20 years of biopharmaceutical experience at Millennium Pharmaceuticals, Novartis, and Merck. Also, the company has additional offices in the USA. The company developed candidate drugs for chronic kidney disease and chronic constipation. The company's products pipelines include ANJ900 Metformin DR, ANJ908 Pradigastat, ANJ810 MCL1 Inhibitor and ANJ114 HCK Inhibitor. ANJ900 Metformin DR is designed for gut-targeted delivery of metformin and is in Phase 3 clinical trials for Type 2 diabetes (T2D) patients with moderate renal impairment. ANJ908 Pradigastat is in Phase 2 clinical trials to treat chronic idiopathic constipation. The ANJ810 MCL1 Inhibitor can specific killing cancer cells in preclinical models. ANJ114 HCK Inhibitor can treat myeloid leukemia.
Current Investors
Kaitai Capital, FengHe Fund Management, Wisdomont Capital

Request a demo to show more

Primary Industry
Pharmaceuticals
Sub Industries
Biotechnology, Pharmaceutical Research & Development, Molecular Chemicals, Medicinal Chemicals & Botanicals
Website
www.anjipharma.com
Verticals
HealthTech
Company Stage
Series B
Total Amount Raised
Subscriber access only

Key Contacts

Name Position Start Date End Date Vcard Bio
General Manager BM
BM Board Member
Name Firm Deal Date Number Of Deals Vcard
AI LP
AI LP
AI Active Investor LP Lead Provider

Want to see more?

Request a demo for full access to this profile.

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.
Sign in Request demo